MeduGate LMS;

10th Nov, 2026 12:00 AM

Test

FDA Approves Pimicotinib for Symptomatic TGCT

The FDA has approved pimicotinib (Pimjetmi, EMD Serono) for treating patients with symptomatic tenosynovial giant cell tumors (TGCTs) for which surgical resection will potentially cause worsening functional limitations or severe morbidity.

Pimicotinib, a CSF-1R TKI, joins two others already on the US market for the indication: vimseltinib and pexidartinib.

Distinguishing pimicotinib from the competition, a Serono press release said the agent showed the highest objective response rate (ORR) seen in a phase 3 trial of a systemic therapy for TGCT, and that it's a potential "best-in-class" CSF-1R inhibitor for the condition.

TGCTs are rare, benign, but locally aggressive soft tissue tumors, originating in the synovial lining of joints, bursae, and tendon sheaths. Symptoms include joint pain, stiffness, swelling, and reduced range of motion, and untreated or recurrent cases can lead to irreversible bone and joint damage.

Pimicotinib was approved based on the MANEUVER trial, which randomized 63 patients to 50 mg once daily of pimicotinib and 31 to placebo. Patients had no previous exposure to a CSF-1R inhibitor.

SUGGESTED FOR YOU

The ORR at week 25, the primary endpoint, was 54% in the pimicotinib arm vs 3% in the placebo arm. At a median follow-up of 14.3 months, the pimicotinib ORR climbed to 76.2%, and nearly 94% of patients had a reduction in tumor size at data cut-off, according to findings presented at the 2025 European Society for Medical Oncology Congress.

As for symptoms, patients who received pimicotinib had significant improvements in range of motion, physical function, pain, and stiffness, relative to the placebo group.

Grade 3 or 4 treatment-emergent adverse events were reported in 35% of patients on pimicotinib, most commonly increased blood creatine phosphokinase (13%) and increased blood pressure (6%). There was no evidence of cholestatic hepatotoxicity, drug-induced liver injury, or hair/skin hypopigmentation with pimicotinib.

The prescribing information includes warnings and precautions for hepatotoxicity, embryo-fetal toxicity, and increased serum creatinine without affecting renal function.

The recommended pimicotinib dosage is 50 mg orally once daily with or without food.

M. Alexander Otto is a physician assistant and award-winning journalist. He is also an MIT science journalism fellow. Email: aotto@medscape.net

Dive Deeper

Commonly Asked by HCPs

Q: How are CSF-1R inhibitors used in the treatment of tenosynovial giant cell tumors?

A: CSF-1R inhibitors target the signaling pathway that drives macrophage-rich TGCT biology and are used to reduce tumor burden and improve pain, stiffness, and range of motion. Clinicians researching this class typically review indications, expected response patterns, durability of benefit, and how these agents compare with surgery or observation.

Read full answer

Q: How do clinicians choose among available systemic options for recurrent TGCT?

A: Choice among systemic TGCT options usually depends on symptom severity, prior treatment exposure, toxicity profile, and the need for durable functional improvement. Clinicians commonly compare efficacy, tolerability, monitoring burden, and contraindications across available agents when deciding whether medical therapy is appropriate for recurrent or unresectable disease.

Read full answer

Q: What adverse effects and monitoring are important with CSF-1R inhibitor therapy?

A: Common safety considerations with CSF-1R inhibitors include hepatotoxicity risk, blood pressure changes, laboratory abnormalities, and other treatment-emergent adverse events. Clinicians also review pregnancy avoidance, baseline and follow-up liver testing, and monitoring for renal-related laboratory changes that may not reflect true kidney injury.

Read full answer

Q: When should systemic therapy be considered instead of surgical resection for TGCT?

A: Systemic therapy is generally considered when surgical resection is likely to worsen function, cause substantial morbidity, or be unlikely to achieve durable control. Research on TGCT management typically focuses on balancing symptom burden, joint preservation, recurrence risk, and the potential benefits of medical therapy versus operative intervention.

Read full answer

Q: What is the standard management approach for symptomatic tenosynovial giant cell tumors?

A: Management of symptomatic TGCT usually centers on surgery when resection is feasible, but treatment planning also considers tumor location, recurrence risk, functional impact, and the likelihood of morbidity from surgery. For unresectable, recurrent, or high-morbidity cases, systemic therapy is increasingly part of the treatment discussion alongside orthopedic and oncology input.

Read full answer